Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Completed · Phase 3
Conditions studied: Acquired Thrombotic Thrombocytopenic Purpura
In brief
The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).
Key facts
- Study ID
- NCT02878603
- Run by
- Sanofi
- People needed
- 104
- Starts
- 2016-10-06
- Expected to finish
- 2020-10-23
- Last updated by the study team
- 2022-03-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Completed the Final (28 day) follow-up visit in Study ALX0681-C301.
- >= 18 years of age at the time of signing the informed consent form.
- Provided informed consent prior to initiation of any study specific activity/procedure.
You may not qualify if…
- Not being able/willing to comply with the study protocol procedures.
- Currently enrolled in a clinical study with another investigational drug or device.
Where it is running
- Investigator site — St Louis, Missouri, United States
- Investigator site — Valhalla, New York, United States
- Investigator Site — Durham, North Carolina, United States
- Investigator Site — Columbus, Ohio, United States
- Investigator Site — Oklahoma City, Oklahoma, United States
- Investigator site — Pittsburgh, Pennsylvania, United States
- Investigator Site — Charleston, South Carolina, United States
- Investigator site — Greenville, South Carolina, United States
- Investigator site — Vienna, Austria
- Investigator site — Antwerp, Belgium
- Investigator site — Brussels, Belgium
- Investigator site — La Louvière, Belgium
- Investigator site — Leuven, Belgium
- Investigator Site — Halifax, Canada
- Investigator Site — Québec, Canada
- Investigator Site — Toronto, Canada
- Investigator Site — Brno, Czechia
- Investigator Site — Olomouc, Czechia
- Investigator site — Caen, France
- Investigator site — Lille, France
- Investigator site — Marseille, France
- Investigator site 1 — Paris, France
- Investigator site 2 — Paris, France
- Investigator Site — Budapest, Hungary
- Investigator Site — Debrecen, Hungary
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.